Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone and Eribulin in Advanced Solid Tumors and TNBC
NCT02014337Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Jan 2014
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of mifepristone in breast cancer, ovarian epithelial cancer, sarcoma and 3 more, sponsored by Corcept Therapeutics. Primary endpoint: Maximum Tolerated Dose and Recommended Phase 2 Dose at 28 days. Started Jan 2014; status: completed.
02
Drugs
mifepristone
03
Conditions
breast cancerovarian epithelial cancersarcomanon-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT02014337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02014337.